Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 DiabetesMichael J. Haller, W. J. Russell, Jessica Miller et al.|Diabetes Care|2018Cited by 183
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J. Haller, Louis H. Philipson, S. Alice Long et al.|Diabetes|2019Cited by 132